Revenio Group Oyj/€REG1V
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Revenio Group Oyj
Revenio Group Oyj is a company focused on providing medical diagnostic solutions, primarily in the fields of ophthalmology. It is known for its innovative products, such as tonometers for eye pressure measurements, which are important in glaucoma examinations. Founded in Finland, the company has its headquarters in Vantaa. Revenio leverages its specialized expertise in medical technology to address specific healthcare needs, with a strategic focus on precision, reliability, and ease of use in its devices. The company's geographic footprint extends across multiple international markets, facilitated by a network of distributors and partners.
- Ticker
- €REG1V
- Sector
- Health
- Primary listing
- XHEL
- Employees
- 765
- Headquarters
- Vantaa, Finland
- Website
- www.reveniogroup.fi
REG1V Metrics
BasicAdvanced
€441M
21.26
€0.49
0.88
-
Price and volume
Market cap
€441M
Beta
0.88
52-week high
€23.20
52-week low
€12.24
Average daily volume
73K
Financial strength
Current ratio
0.583
Quick ratio
0.335
Long term debt to equity
0.86
Total debt to equity
1.731
Dividend payout ratio (TTM)
0.30%
Profitability
EBITDA (TTM)
20.1
Gross margin (TTM)
67.85%
Net profit margin (TTM)
10.54%
Operating margin (TTM)
14.09%
Effective tax rate (TTM)
28.46%
Revenue per employee (TTM)
€160,000
Management effectiveness
Return on assets (TTM)
3.57%
Return on equity (TTM)
10.33%
Valuation
Price to earnings (TTM)
21.261
Price to revenue (TTM)
2.242
Price to book
2.11
Price to tangible book (TTM)
-1.9
Price to free cash flow (TTM)
33.754
Free cash flow yield (TTM)
2.96%
Free cash flow per share (TTM)
0.31
Growth
Revenue change (TTM)
15.97%
Earnings per share change (TTM)
-27.25%
3-year revenue growth (CAGR)
8.25%
10-year revenue growth (CAGR)
19.02%
3-year earnings per share growth (CAGR)
-11.88%
10-year earnings per share growth (CAGR)
9.46%
3-year dividend per share growth (CAGR)
6.92%
10-year dividend per share growth (CAGR)
9.15%
What the Analysts think about REG1V
Analyst ratings (Buy, Hold, Sell) for Revenio Group Oyj stock.
Analyst projections of the future price of Revenio Group Oyj stock.
Bulls say / Bears say
Visionix gives Revenio a broader eye-care portfolio, entry into OCT and roughly 2.5 times the addressable market, creating scope to cross-sell products across more customers and regions. (Revenio Group)
Revenio targets 5–10% organic sales growth a year and a 25% adjusted EBITDA margin by 2029, with more than €20 million of Visionix synergies expected to support those goals. (MFN.se)
A partnership to place DRSplus screening devices in EyeCheq stations could open new point-of-care channels beyond traditional eye clinics and support wider use of automated eye screening. (Inderes)
The legacy Revenio business was flat in Q2, while 2026 sales guidance allows for continued soft demand and slower customer activity. That leaves the underlying growth outlook less convincing than the acquisition-led headline growth suggests. (Inderes)
The Visionix deal left net debt at €238 million and leverage at 5.3 times adjusted EBITDA, leading to an €80 million rights offering. The financing burden and resulting share issuance risk weigh on existing shareholders while the company works to reduce debt. (Investing.com, Revenio Group)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
REG1V Financial Performance
Revenues and expenses
REG1V Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing REG1V
AllUSDEURGBP
Fund name | Fund size | €REG1V weighting |
|---|---|---|
Vanguard FTSE Global All-cap$VALU | $199M | 0.00% |
Vanguard FTSE Global All-cap€VGLA | €171M | 0.00% |
Vanguard FTSE Global All-cap£VALL | £147M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.